| Document Date: 2010-07-28 00:50:35
Open Document File Size: 55,01 KBShare Result on Facebook
City Tokyo / Tarrytown / / Company Regeneron Pharmaceuticals Inc. / Agensys Inc. / Astellas Pharma Inc. / Regeneron Research Laboratories / / Country Japan / United States / / Currency USD / / Event Business Partnership / FDA Phase / / IndustryTerm commercialized product / biopharmaceutical / indispensable technology / treatment of gout / diseases / pharmaceutical products / pharmaceutical / antibody products / / MedicalCondition central retinal vein occlusion / cancer / metabolic diseases / rheumatoid arthritis / certain cancers / pain / gout / inflammatory conditions / diseases / infectious diseases / age-related macular degeneration / / Person George D. Yancopoulos / Shinichi Tsukamoto / Masafumi Nogimori / Drug Discovery / / Position Chief Scientific Officer / President / Senior Vice President / global category leader / President & CEO / established leader / / Product VelocImmune / Vesicare / Prograf / ARCALYST / ARCALYST® (rilonacept) Injection / / ProvinceOrState New York / / Technology neuroscience / Antibody Technology / antibodies / VelocImmune technology / indispensable technology / drug development / / URL www.regeneron.com / http /
SocialTag |
FOR IMMEDIATE RELEASE Press Release Astellas to Pay $295 Million to Extend License of Regeneron’s VelocImmune® Antibody Technology through 2023 Tarrytown, NY and Tokyo, Japan – (July 28, 2010) –Regeneron Pharmaceu